Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03023202 · ClinicalTrials.gov registry record
UWCCC Molecular Tumor Board Registry
A clinical trial of Hematologic Neoplasms and Solid Neoplasm, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT03023202: Recruiting study of Hematologic Neoplasms and Solid Neoplasm, sponsored by University of Wisconsin, Madison.
NCT03023202 is a study of Hematologic Neoplasms and Solid Neoplasm that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 10,000 participants, above the 526-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (1801% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03023202, a study of Hematologic Neoplasms and Solid Neoplasm, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Primary Outcome
How often the molecular tumor board's recommendations are accepted
Conditions Studied
Interventions
- OTHER PMMTB (Precision Medicine Molecular Tumor Board)
Study Locations (1)
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2016-03-30 |
| Est. Completion | 2027-03 |
What NCT03023202 shows while recruiting
NCT03023202 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 526-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (1801% higher).
The record links to 2 conditions, with Hematologic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PMMTB (Precision Medicine Molecular Tumor Board) is the first listed.
NCT03023202 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03023202 about?
NCT03023202 is a clinical study titled "UWCCC Molecular Tumor Board Registry". This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
What is the current status of trial NCT03023202?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2016-03-30. Estimated completion is 2027-03.
What conditions does trial NCT03023202 study?
This clinical trial studies the following conditions: Hematologic Neoplasms, Solid Neoplasm.
What interventions are being tested in trial NCT03023202?
The interventions under investigation include: PMMTB (Precision Medicine Molecular Tumor Board) (OTHER).
Who is sponsoring clinical trial NCT03023202?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03023202 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03023202's enrollment target sits among peer trials
10,000 1st of 20 higher than 20 of 20 other Hematologic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI